National Health (Weighted average disclosed price - interim supplementary disclosure cycle) Determination 2012 (No. PB 58 of 2012)
6Adjusted approved ex‑manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
Start here
Get a plain-English read of 6
Turn the raw legal text into a practical explanation grounded in National Health (Weighted average disclosed price - interim supplementary disclosure cycle) Determination 2012 (No. PB 58 of 2012).
6 Adjusted approved ex‑manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
For paragraph 99ADB(4) of the Act, the adjusted approved ex‑manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 4 of this instrument.